Alterations in the plasma metabolome associated with maternal smoking during the first trimester and fetal growth

Wadzanai Masvosva [1], Taija Voutilainen [1], Marko Lehtonen [1], Retu Haikonen [2], Seppo Auriola [1], Leea Keski-Nisula [3,4], Jaana Rysä [1], Olli Kärkkäinen [1]

Affiliations:

[1] School of Pharmacy, University of Eastern Finland

[2]Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland

[3]Institute of Clinical Medicine, School of Medicine, University of Eastern Finland, Finland

[4]Department of Obstetrics and Gynecology, Kuopio University Hospital, Finland

Correspondence: Dr. Olli Kärkkäinen, School of Pharmacy, University of Eastern Finland, Yliopistonrinne 3, 70210 Kuopio, Finland; olli.karkkainen@uef.fi

Plain language summary

Tobacco smoking during pregnancy has been associated with an increased risk of adverse outcomes like low birth weight. In this study, we measured changes in the circulating metabolome linked to maternal smoking in the first trimester and correlated these changes to the growth of the fetus. Maternal smoking during the first trimester of pregnancy was associated with an altered metabolite profile linked to endocrine disruption and increased oxidative stress. Furthermore, some of these changes were associated with reduced fetal growth.

Abstract

Tobacco smoking during pregnancy has been associated with an increased risk of adverse outcomes like low birth weight. This study determined changes in the circulating metabolome linked to maternal smoking in the first trimester and correlated these changes to the growth of the fetus. The circulating metabolome was examined from first trimester plasma samples by non-targeted (global) liquid chromatography mass spectrometry-based metabolite profiling of 227 pregnant women (99 smokers and 117 non-smokers) from the Kuopio Birth Cohort Study. Tobacco smoking was self-reported through a questionnaire and verified with cotinine measurements from plasma samples. In summary, 64 significant differences were observed between the groups after correction for multiple testing e.g. in metabolites indicating endocrine disruption (e.g., dehydroepiandrosterone sulfate [DHEA-S], VIP=2.70, d=0.68, p<0.0001), metabolites associated with oxidative stress (e.g., bilirubin, VIP=2.00, d=0.50, p<0.0001) and lipid metabolism (e.g., LysoPC 16:1, VIP=2.07, d=0.51, p<0.0001). Some of these metabolites, e.g., DHEA-S and bilirubin, correlated with low birth weight, and some, e.g. LysoPC 16:1, correlated with small head circumference at birth. In conclusion, maternal smoking during the first trimester of pregnancy was associated with an altered metabolite profile linked to endocrine disruption and increased oxidative stress.

Keywords: tobacco, smoking, pregnancy, metabolome, metabolomics

Introduction

Smoking has been recognized as the most important preventable cause of mortality in the world[1]. Approximately 10% of women worldwide smoke during pregnancy, although the rate varies greatly between regions and countries[2]. Smoking during pregnancy exposes the fetus to the harmful effects of tobacco.

Nicotine is the main psychoactive ingredient in tobacco, and it can easily cross the placental barrier. Nicotine concentrations in fetal circulation have been reported to be even 15% higher than those detected in the maternal circulation[3]. Nicotine causes a general constriction of blood vessels, decreasing the delivery of nutrients to the developing fetus. Carbon monoxide is another harmful chemical present in tobacco smoking; it binds avidly to hemoglobin and subsequently reduces the amount of oxygen being carried to the fetus thus increasing the risk for hypoxia[4]. During pregnancy, even low levels of tobacco smoking have been associated with an increased risk of adverse outcomes like low birth weight[5], sudden infant death syndrome[6], behavioral and neurodevelopmental impairments[7] and asthma and obesity[8]. The effects of maternal tobacco smoking during pregnancy may be permanent and not just be evident from childhood but also last into adulthood, for example, leading to elevated blood pressure, endothelial dysfunction, and even changes in renal structure[9].

65 Only a limited number of studies have investigated changes in the metabolite profile
66 associated with smoking during pregnancy. Gray et al. (2010) observed metabolic
67 differences in the umbilical venous samples taken at birth between smoking exposed and
68 non-exposed neonates[10]. For example, they reported lower concentrations of
69 lysophosphatidylcholine (LysoPC) 16:0, LysoPC18:0, and LysoPC 18:1 in the umbilical
70 venous samples from smoking exposed newborns. Indeed, low lysophosphatidylcholine
71 levels have been associated with a lowered birth weight in the newborns[11]. Furthermore,
72 Rolle-Kampczyk et al. (2016) examined the impact of maternal smoking on endogenous
73 metabolites in 40 maternal and umbilical blood samples. They revealed significant
74 alterations in several metabolites, including sphingomyelin SM 26:0 and several
75 phosphatidylcholines (PCs), in both mothers and children within the smoking-exposed
76 group[12]. In their evaluation of urine samples from the first and second antenatal visit of
77 105 pregnant Afro-American women, Tan et al. (2022) revealed that 47 metabolites that
78 have been linked with increased inflammation and decreased oxidation of amino acids
79 were associated with high cotinine levels. These detected metabolites also have potential
80 health-related effects during gestation with the possibility to influence several
81 pathophysiological pathways causing adverse birth outcomes[13]. However, to our
82 knowledge, there have been no studies investigating tobacco smoking associated
83 alterations in the metabolite profiles during the first trimester, which is a crucial time
84 during pregnancy since it is the period of organogenesis [14].
85

86 Therefore, here we wanted to examine the changes in the maternal metabolome
87 associated with smoking in the first trimester to increase our understanding of the
88 metabolic consequences of gestational smoking. In this nested case-control study, our aim
89 was to identify cigarette smoking-induced changes in the circulating metabolome by
90 applying a non-targeted, or global, metabolomics approach in the evaluation of first
91 trimester plasma samples of women in the Kuopio Birth Cohort (KuBiCo). In addition, we
92 aimed to investigate how these changes in the metabolome could be associated with fetal
93 growth.
94

95 **Methods**

96 Study Cohort

97 This study is part of Kuopio Birth Cohort (KuBiCo), which is a joint research effort between
98 the University of Eastern Finland (UEF), Kuopio University Hospital (KUH), and National
99 Institute for Health and Welfare (THL)[15]. The KuBiCo study was approved by the Research
100 Ethics Committee, Hospital District of Central Finland in 15.11.2011 and all participants
101 have given their written electronic consent. The study was conducted in accordance with
102 the Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical
103 studies[16].
104

105 The cohort consists of women from Finnish Northern Savo county expected to have
106 delivery at KUH. The participants were recruited during their first trimester routine

107 antenatal visit by a health care nurse, during weeks 6-9 of gestation mainly from the
108 outpatient maternity clinics. Additionally, these women filled in several questionnaires
109 which evaluated their background risk for ongoing pregnancy in the Pikku-Haikara system
110 designed in the Kuopio University Hospital for pregnant women. The information on
111 gestational smoking/tobacco exposure was gathered via standardized questionnaires.
112 Between the years 2012 and 2020, approximately 5000 first trimester plasma samples were
113 collected routinely for the KuBiCo study at the same time with the first trimester fetal
114 screening samples. This study utilizes ethylenediaminetetraacetic acid (EDTA) plasma
115 samples, which were kept at -80°C until the metabolomics analysis, collected during the
116 first trimester between years 2013 and 2018[15].

117

118 To allow the samples to be used for this study, the subjects of interest should be pregnant
119 with a parity of six or less, with the preference to use samples from their first pregnancies.
120 Participants' self-reported tobacco use gathered in an online questionnaire was used to
121 evaluate tobacco smoking during pregnancy [17]. Tobacco smoking was defined as taking any
122 tobacco products after conception. There was no limitation on the number of cigarettes
123 smoked per day. The smokers were compared against controls who recorded not having
124 smoked at all during pregnancy. Since it is evident that self-reported data is not 100%
125 reliable, we initially selected more controls than tobacco smokers. After liquid
126 chromatography mass spectrometry (LC-MS) analysis, we excluded seven subjects from the
127 control group as they had elevated levels of nicotine or cotinine in their blood sample.

128 This led to the selection of two study groups: a control group with 117 samples of women
129 who had not smoked during pregnancy and a study group with 99 samples of women who
130 had smoked during their pregnancy but did not report any alcohol use during pregnancy.
131 We excluded alcohol users, since alcohol use during pregnancy is more common in those
132 who smoke and is known to influence the metabolome during pregnancy[18]. The analysis
133 order of the samples was randomized using a random number generation algorithm.

134

135 This study used the following descriptive characteristics collected from the KUH birth
136 registry: maternal age, height and weight, body mass index (BMI; kg/m^2), parity, gravidity,
137 duration of pregnancy at birth, length of maternal hospital stay after birth, relationship
138 status, and in the smoking women, the daily amount of cigarettes before and during
139 pregnancy to allow the estimation of the smoking index. Additionally, in the newborns, data
140 was collected on gender, birthweight, head circumference, placental weight, APGAR scores
141 (1 and 5 minutes), need for special or neonatal intensive care, ventilation assistance or
142 intubation, need for postnatal antibiotic treatment or phototherapy, and the presence of
143 any congenital malformations.

144

145 Non-targeted LC-MS based metabolite profiling

146 The metabolomics analysis was performed according to previously released guidelines with
147 some modifications[19]. In brief, sample preparation was done by thawing plasma samples in

148 ice-cold water; the samples were maintained in ice-cold water during all waiting periods
149 before they were transferred for sample preparation into 96 well plates (Thermo Scientific
150 Nunc) embedded on wet ice and covered with a filter plate (Captiva ND filter plate 0.2 um
151 PP 5/pk, Part no. A5969002, 732-2669). Then, 320 µL of cold acetonitrile (HPLC LC-MS Grade
152 83640.320, VWR) were dispensed into the filter plate well. The plasma samples were then
153 vortexed for 10 seconds at maximum speed and subsequently 80 µL of the plasma
154 samples were added to the same well with acetonitrile. The Andrew Alliance robot with a
155 Microplate shaker (519.4004.14HAK, Vacuum + 518.6093.160UY, 8-ch 1200) was used for
156 sample preparation. Preparation of the quality control sample (QC) was done by adding 10
157 µL of each sample to the same clean microcentrifuge tube and mixing. These QC samples
158 were injected at the beginning of the analysis to stabilize the liquid chromatography (LC)
159 column. QC samples were also tested after every 12th sample in the analysis runs to assess
160 batch and drift correction and data quality analysis, as well as in the tandem mass
161 spectrometry analyses. The samples were precipitated by centrifuging the plate for 5
162 minutes at 700xg at 4 °C after which, the filter plate was sealed tightly to avoid sample
163 evaporation prior to the following metabolomics analysis
164
165 The metabolomics analysis used ultrahigh performance liquid chromatography (UPLC) with
166 a Thermo Q Exactive Hybrid quadrupole-orbitrap mass spectrometer (MS). Samples were
167 analyzed using two chromatographic techniques, reversed phase (RP) and hydrophilic
168 interaction (HILIC), in both positive and negative polarities. The RP chromatography column
169 was Zorbax Eclipse XDB-C18. The mobile phase A was H2O + 0.1 % HCOOH, mobile phase B

170 was MeOH + 0.1 % HCOOH with a 16.5 min gradient and a flow rate of 0.4 ml/min. The
171 HILIC chromatographic set-up used an Acquity BEH amide column, Mobile phase A: 50%
172 acetonitrile + 20 mM ammonium formate buffer, B: 90 % acetonitrile + 20 mM ammonium
173 formate buffer, 12.5 min gradient, 0.6 ml/min.
174
175 Both negative and positive electrospray ionization (ESI) were used in both analytical modes.
176 ESI settings were ray voltage 3.5 kV for positive and 3.0 kV for negative, max spray current
177 100, flow rates 40 for sheath gas, 10 for auxiliary gas, and 2 for spare gas (as arbitrary units
178 for ion source), S-lens RF level 50 V, capillary and probe heater temperature 300 °C. A full
179 scan range from m/z 60 to 700 in the HILIC modes and 120 to 1200 in the RP modes with a
180 resolution of 70 000 (m/Δm, full width at half maximum at 200 u) and an automated
181 injection time and gain control targeted at 1 000 000 ions. The m/z ranges were limited to
182 ions of interest in each mode to increase the sensitivity of the measurement. In the tandem
183 mass spectrometry (MS/MS), three peaks with apex triggers ranging from 0.2 up to 3 s were
184 selected for MS/MS fragmentation with 15 s dynamic exclusion. A normalized collision
185 energy at 20, 30, and 40, was used in MS/MS with a mass resolution of 17 500 (m/Δm, full
186 width at half maximum at 200 u), an automated gain targeted at 50 000, and an isolation
187 window of 1.5 m/z.
188
189 Data analysis was done using MS-dial software 4.90 version for peak picking, peak
190 alignment, and metabolite identification. Data collection had an MS1 tolerance of 0.005 and
191 an MS2 tolerance of 0.025. The settings for the retention time parameters started at 0.5

192 minutes and stopped at the end of the analytical run, collecting all the features within the
193 mass ranges set for each mode. Peak detection parameters had a minimum peak height of
194 300,000 with an amplitude smoothing level of 3 scans, minimum peak width of 8 scans, and
195 a mass slice width of 0.1 Da. Deconvolution parameters had a sigma window value of 0.5
196 with 0 as the amplitude cut-off. The identification was performed against the University of
197 Eastern Finland in-house database with accurate mass tolerance of MS1 0.008 Da and MS2
198 0.025 Da. Automatic identifications were verified and corrected manually. Adduct ion
199 settings of [M+H]+, [M+NH4]+, [M+Na]+, [M+K]+, [M+Li]+, [M+ACN+H]+, [M+H-H2O]+, [M+H-
200 2H2O]+, [2M+H]+ were utilized in positive polarity and [M-H]-, [M-H2O-H]-, [M+Na-2H]-,
201 [M+Cl]-, [M+FA-H], [M+Hac-H]-, [2M-H]- when we applied negative polarity. The alignment
202 parameters settings had a retention time of 0.05 mins with MS1 tolerance 0.015 for
203 molecular features detected in at least 30% of the samples in one of the groups with a gap-
204 filling by compulsion.
205
206 Preprocessing of the data (data quality analysis, drift and batch effect correction,
207 imputation of missing values), and statistical analyses were done using the R-package
208 notame[19].
209
210 The identification of metabolites focused on those molecular features with p-values <0.05.
211 The molecular features were grouped into 4 levels according to the community
212 guidelines[20]. Level 1 identification included those compounds confirmed by matching to

213 exact mass, isotope pattern, retention time, and MS2 fragmentation with chemical
214 standards from the in-house library. Level 2 identification comprised putatively annotated
215 compounds, identified by matching to exact mass and MS2 spectra against public libraries.
216 Level 3 identification referred to the compounds identified at the chemical group level but
217 lacking an exact compound identification, while level 4 consisted of unknown compounds.

218 Statistical analysis

219 Differences between background characteristics were evaluated with Welch's t-test and
220 Chi^2 test. With respect to the metabolomics data, univariate analysis was done with Cohen's
221 d effect sizes with p-values being calculated using Welch's t-test. Since molecular features
222 in metabolomics analysis are not independent, the number of principal components
223 needed to explain 95% of the variance in the metabolomics data in the principal
224 component analysis (PCA) was used and to account for multiple testing the Bonferroni
225 method was applied. Here, 184 PCs were needed to explain 95% of the variation in the
226 metabolomics data, therefore the α level was adjusted to 0.0003. Findings with p-values
227 between 0.05 and 0.0003 were considered to be trends. Additionally, we used partial-least-
228 squares discriminant analysis (PLS-DA) to identify the variables that contributed most
229 extensively to the variation between smoking and nonsmoking pregnant women in a
230 multivariate analysis. Cross-validation was done by splitting the dataset into 7 subsets.
231 Variable importance to the projection (VIP) values from PLS-DA are reported for each
232 variable. Correlations between molecular features and birth weight or head circumference
233 were calculated using linear regression. We used SIMCA 17.0 for multivariate data analysis

solution, whereas we utilized the notame (version 0.3.0) R-package for the calculation of univariate statistics for metabolomics data[19]. JASP (version 0.17) software was used to calculate statistics related to the background characteristics between the non-smoking and smoking groups. Figures were made using Prism (GraphPad software Inc. version 10.0) and SIMCA version 17.0.

239 **Results**

240 The characteristics of the pregnant women and their newborns women are shown in Table
241 1. Smokers had a significantly lower parity, higher BMI values, pre-pregnancy weights and
242 were less likely to be in a relationship when compared to the nonsmoking controls. On
243 average, the newborns of smokers had a lower birth weight and head circumference when
244 compared to control newborns. Furthermore, they needed more antibiotic therapy and
245 treatment in the intensive care unit than the controls.

246

247 A total of 9600 molecular features were observed in the non-targeted metabolomics
248 analysis (Supplementary table 1). The PCA analysis revealed that 184 principal components
249 were required to explain 95% of the overall variance in the metabolomics data. These
250 results were used to adjust the α level to 0.0003 to account for multiple testing using
251 Bonferroni correction after which a total of 1109 molecular features had a p-value < 0.05,
252 and 193 molecular features had a p-value < 0.0003 (Figure 1). The PLS-DA model also
253 revealed a difference between the first trimester plasma samples of nonsmokers and
254 smokers (6 components, cum R2Y = 0.99, Q2 = 0.70) (Figure 1, Supplementary table 1).

255

256 Our results showed that the circulating metabolite profiles from the first trimester plasma
257 samples of smoking pregnant women were different from the nonsmoking controls (Figure
258 1). The identified metabolites were grouped according to the human metabolome database

259 (HMDB)[21]. For example, smokers had significantly lower levels of bilirubin and biliverdin,
260 and significantly higher levels of dehydroepiandrosterone sulfate (DHEA-S) (Figure 2). High
261 levels were also evident for several exogenous compounds e.g. cotinine, nicotine, and
262 trigonelline along with xanthines like caffeine, paraxanthine, and theophylline in the
263 smokers when compared to the controls.

264

265 The correlation analysis indicated that birth weight was also positively associated with the
266 levels of biliverdin (r = 0.20, p = 0.0029), creatine (r = 0.15, p = 0.0029) and PC38:6
267 (16:0_22:6) (r = 0.14, p = 0.0035) and negatively associated with those of cotinine (r = -0.18,
268 p = 0.00096), Asp-Phe (r-0.15, p = 0.0026), DHEA-S (r = -0.15, p = 0.0265) and AC14:1 (r =-
269 0,13, p = 0.0049). Head circumference was negatively associated with the levels of 7a-
270 hydroxy-3-oxo-4-cholestenoic acid (r = -0.18, p=0.001), cotinine (r = -0.17,p=0.0013), LysoPC
271 16:1 (16:1/0:0) (r = -0.16, p = 0.0019), LysoPC 16:1 (0:0/16:1) (r = -0.15, p = 0.0028), AC 06:0 (r
272 = -0.15, p = 0.0037) and lenticin (r = -0.14, p = 0.0043). These results are shown graphically
273 in Figure 3 and Figure 4. Furthermore, levels of nicotine, cotinine and 3-hydroxypyridine
274 correlated (r values between 0.56-0.76 and p values < 0.0001) with the self-reported
275 number of cigarettes smoked per day both before and during pregnancy (Supplementary
276 Figure 1).

277

278 **Discussion**

279

280 We demonstrated that the profiles of the first trimester circulating metabolites of smoking
281 pregnant women were different from those of non-smoking controls. Furthermore, some
282 of these differences were associated with the known unfavorable effects of smoking such
283 as low birth weight and smaller head circumference. Key differences in the metabolite
284 profiles of smoking pregnant women were detected in several factors e.g., elevated levels
285 of DHEA-S and reduced levels of bilirubin and ergothioneine, as well as in certain specific
286 small molecules which are linked directly to the tobacco smoking (nicotine, cotinine, 3-
287 hydroxypyridine) and a higher coffee intake (caffeine, paraxanthine, trigonelline). This
288 finding is in line with the published literature that there is an association between higher
289 nicotine/ cotinine levels and unfavorable fetal/ neonatal effects like low birth weight [22].
290 However, this study expands these findings by linking also other metabolites such as
291 DHEA-S and bilirubin to fetal and neonatal growth.

292

293 We found that pregnant women who were smokers had high levels of DHEA-S in the first
294 trimester plasma samples, and that these were further associated with the lower birth
295 weight. DHEA-S is as a metabolic intermediate in the biosynthesis of sex steroids [23].
296 Smoking has been shown to influence adrenal hormone production by upregulating the
297 adrenal β-arrestin 1 enzyme, which is involved in the development of hyperaldosteronism
298 and consequently to higher basal levels of DHEA-S[24,25]. The elevated DHEA-S levels are
299 evidence of an endocrine disorder attributable to maternal smoking and it has been

300 reported that endocrine disturbances can be linked to growth retardation and neurological
301 impairments in the newborn[26].

302

303 Moreover, smokers displayed lowered plasma levels of ergothioneine, which is a
304 microbiota-associated antioxidant. Earlier studies have shown that low levels of
305 ergothioneine during pregnancy are associated with negative pregnancy outcomes like pre-
306 eclampsia[27]. Conversely, high ergothioneine levels are associated with health benefits like
307 protection against cardiovascular diseases[28], and this seems to be the case for biliverdin
308 and bilirubin[29], implying that this protective mechanism has become impaired in smokers.
309 Smokers had low levels of two endogenous antioxidant biomarkers i.e., bilirubin and
310 biliverdin, when compared to the controls, a finding which is in line with previous
311 reports[30,31]. Biliverdin is a metabolite formed from the breakdown of hemoproteins; it is
312 further reduced to bilirubin by biliverdin reductase [32]. Low levels of bilirubin have been
313 associated not only with smoking-related respiratory diseases[30], but also with autoimmune
314 diseases like lupus and rheumatoid arthrtis[33]. Thus, the low levels ergothioneine, biliverdin
315 and bilirubin indicate that the pregnant women who smoke have a reduced antioxidative
316 capacity while being subjected to increased oxidative stress; these types of changes could
317 well trigger unfavorable outcomes like growth restrictions [5]. In line, we observed that the
318 presence of low biliverdin levels in the first trimester plasma samples was associated with
319 low birth weights in the newborns.

320

321 Additionally, our study showed a lower abundance of isatin (1H-indole-2,3-dione) in the
322 smoking group when compared to the control group. The levels of isatin have been
323 reported to be lower in smokers due to the impact of monoamine oxidase activity and
324 oxidative stress since monoamine oxidase is the enzyme that metabolizes isatin[34]. An
325 increased level of oxidative stress has been reported to alter the regulation of isatin in the
326 body, where it acts as a neuroprotective agent[35]. It would be enlightening to clarify if low
327 isatin levels would be associated with neurological impairments in newborns.

328

329 Moreover, the metabolomics analysis also showed that the levels of three metabolites
330 linked to tobacco smoking, namely nicotine, cotinine, 3-hydroxypyridine, were significantly
331 increased in blood samples of the tobacco-exposed mothers. Positive correlations were
332 shown between the self-reported number of cigarettes smoked per day both before and
333 during pregnancy with these 3 mentioned metabolites (Supplementary Figure 1). Here,
334 cotinine exhibited a significant negative correlation to birth weight and head
335 circumference. Interestingly, previous studies have shown that the metabolism of nicotine
336 is accelerated during pregnancy; this was assessed by measuring the nicotine metabolite
337 ratio at different gestational weeks[36].

338

339 Furthermore, the observed high levels of metabolites associated with caffeinated products
340 (caffeine, theophylline, paraxanthine and trigonelline) are in line with previous studies that
341 found that smoking pregnant women consume more caffeinated products compared to

342 their nonsmoking pregnant counterparts[37]. It is recognized that the metabolism of
343 compounds present in coffee is reduced during pregnancy[38], and additionally, after
344 crossing the placental barrier, caffeine's metabolism is decreased possibly leading to
345 prolonged effects in the fetus [39]. Previously, an increased coffee intake has been associated
346 with a low birth weight [40] , although here we did not observe correlations between birth
347 weight and the levels of coffee metabolites.
348

349 Additionally, we detected significant alterations in the concentrations of lipids; higher levels
350 (e.g., LysoPC 16:1), and lower levels (e.g., PC 38:6) in the tobacco smoking group.
351 Disturbances in lipid levels have been associated with negative developmental effects in
352 the newborns' brains and retinas [41]. Also here, the high levels of LysoPC 16:1 were
353 associated with a small head circumference whereas low levels of PC 38:6 were linked with
354 a reduced body weight at birth.
355

356 The limitations of the current study include the self-reported use of tobacco smoking by
357 the pregnant women. Although we had access to nicotine and cotinine levels which made it
358 possible to detect current users, there might be some cases of pregnant women who were
359 infrequent smokers as the blood samples were taken as a part of routine visits during the
360 first trimester. We also observed some limitations of self-reporting, i.e., there were 7
361 controls that had to be excluded from the study because of high cotinine levels in these

362 samples. Another limitation is the sample size, which was relatively small and limited the
363 statistical power. For example, with a higher sample size, differences in the levels of sterols
364 and lipids could have reached statistical significance (Supplementary table 1). In addition,
365 the population used for this study was mostly from the Northern Savo area of Finland,
366 likely with similar lifestyle factors such as their diet. This could explain the increased
367 abundance of metabolites like paraxanthine which might not be evident in other
368 populations that do not consume as many caffeinated products. Therefore, a similar study
369 would need to be done with a different target population. Additionally, for the correlation
370 analysis, the time between the 1st trimester samples collection and its linkage to the health
371 of the newborns, means that many positive and negative changes could have taken place
372 in the remaining months of the pregnancy. The maternal metabolite profile may have
373 significantly altered during this time, and this would be reflected in the attained results[42].
374 Moreover, the plasma samples were stored in -80˚C for between 5-10 years before
375 analysis. Although these are the recommended conditions for plasma sample storage[43],
376 measuring metabolomes is highly sensitive and there could be a possibility of it being
377 altered during the storage from example in case of lipids. However, the storage times were
378 similar between the study groups making the results comparable between the groups.
379
380 In conclusion, the current study successfully compared the differences between smoking
381 and nonsmoking pregnant women in the circulating metabolome as analyzed from plasma
382 samples taken in the first trimester. Tobacco smoking during early pregnancy was
383 associated with alterations in metabolites associated with a disruption of endocrine

384 functions and increased oxidative stress and linked with a restricted growth of the fetus.

385 Further studies will need to be conducted in several different populations in order to widen

386 the generalizability of these results.

387

Acknowledgements

This work was supported by the Finnish Ministry of Social Affairs and Health for the VAURAS project, and the Finnish Foundation for Alcohol Studies. This paper belongs to the studies carried out by the Kuopio Birth Cohort consortium (www. KuBiCo.fi) and we thank our colleagues who are responsible for the design and conduct of the KuBiCo. We want to thank Essi Järvelä for assistance with sample collection, Miia Reponen and Juulia Kuparinen for technical assistance with the mass spectrometry analyses, Ewen MacDonald for proof-reading, and the staff of the Department of Obstetrics and Gynecology in Kuopio University Hospital. The authors also want to thank Biocenter Finland and Biocenter Kuopio for supporting the core LC-MS laboratory facility.

Conflict of interest

O.K. is a co-founder of Afekta Technologies Ltd. a company providing metabolomics analysis services. W.M, T.V, M.L, R.H, S.A, L.K-N, J.R declare no conflicts of interest.

Data Sharing Statement

The data that support the findings of this study are available on request from the corresponding author, OK. The study plan approved by the ethical committee and the participant consent terms preclude public sharing of these sensitive data, even in anonymized form.

408 **References**

409 1. Reitan T, Callinan S. Changes in Smoking Rates Among Pregnant Women and the
410 General Female Population in Australia, Finland, Norway, and Sweden. *Nicotine Tob Res*
411 *Off J Soc Res Nicotine Tob*. 2017;19(3):282-289. doi:10.1093/ntr/ntw188

412 2. Havard A, Chandran JJ, Oei JL. Tobacco use during pregnancy. *Addict Abingdon Engl*.
413 2022;117(6):1801-1810. doi:10.1111/add.15792

414 3. Wickström R. Effects of nicotine during pregnancy: human and experimental evidence.
415 *Curr Neuropharmacol*. 2007;5(3):213-222. doi:10.2174/157015907781695955

416 4. Kubista E. [Smoking in pregnancy]. *Wien Med Wochenschr 1946*. 1994;144(22-23):529-
417 531.

418 5. Rumrich I, Vähäkangas K, Viluksela M, Gissler M, de Ruyter H, Hänninen O. Effects of
419 maternal smoking on body size and proportions at birth: a register-based cohort study
420 of 1.4 million births. *BMJ Open*. 2020;10(2):e033465. doi:10.1136/bmjopen-2019-033465

421 6. Anderson TM, Lavista Ferres JM, Ren SY, et al. Maternal Smoking Before and During
422 Pregnancy and the Risk of Sudden Unexpected Infant Death. *Pediatrics*.
423 2019;143(4):e20183325. doi:10.1542/peds.2018-3325

424 7. Wehby GL, Prater K, McCarthy AM, Castilla EE, Murray JC. The Impact of Maternal
425 Smoking during Pregnancy on Early Child Neurodevelopment. *J Hum Cap*. 2011;5(2):207-
426 254. doi:10.1086/660885

427 8. Ino T, Shibuya T, Saito K, Ohtani T. Effects of maternal smoking during pregnancy on
428 body composition in offspring. *Pediatr Int Off J Jpn Pediatr Soc*. 2011;53(6):851-857.
429 doi:10.1111/j.1442-200X.2011.03383.x

430 9. Banderali G, Martelli A, Landi M, et al. Short and long term health effects of parental
431 tobacco smoking during pregnancy and lactation: a descriptive review. *J Transl Med*.
432 2015;13:327. doi:10.1186/s12967-015-0690-y

433 10. Peacock JL, Palys TJ, Halchenko Y, et al. Assessing tobacco smoke exposure in
434 pregnancy from self-report, urinary cotinine and NNAL: a validation study using the
435 New Hampshire Birth Cohort Study. *BMJ Open*. 2022;12(2):e054535.
436 doi:10.1136/bmjopen-2021-054535

437 11. LaBarre JL, Puttabyatappa M, Song PXK, et al. Maternal lipid levels across pregnancy
438 impact the umbilical cord blood lipidome and infant birth weight. *Sci Rep*.
439 2020;10(1):14209. doi:10.1038/s41598-020-71081-z

440 12. Rolle-Kampczyk UE, Krumsiek J, Otto W, et al. Metabolomics reveals effects of maternal
441 smoking on endogenous metabolites from lipid metabolism in cord blood of newborns.
442 *Metabolomics Off J Metabolomic Soc*. 2016;12:76. doi:10.1007/s11306-016-0983-z

443 13. Tan Y, Barr DB, Ryan PB, et al. High-resolution metabolomics of exposure to tobacco
444 smoke during pregnancy and adverse birth outcomes in the Atlanta African American
445 maternal-child cohort. *Environ Pollut Barking Essex 1987*. 2022;292(Pt A):118361.
446 doi:10.1016/j.envpol.2021.118361

447 14. Donovan MF, Cascella M. Embryology, Weeks 6-8. In: *StatPearls*. StatPearls Publishing;
448 2024. Accessed October 14, 2024. http://www.ncbi.nlm.nih.gov/books/NBK563181/

449 15. Huuskonen P, Keski-Nisula L, Heinonen S, et al. Kuopio birth cohort - design of a Finnish
450 joint research effort for identification of environmental and lifestyle risk factors for the
451 wellbeing of the mother and the newborn child. *BMC Pregnancy Childbirth*.
452 2018;18(1):381. doi:10.1186/s12884-018-2013-9

453 16. Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT 2023 policy
454 for experimental and clinical studies. *Basic Clin Pharmacol Toxicol*. 2023;133(4):391-396.
455 doi:10.1111/bcpt.13944

456 17. Voutilainen T, Keski-Nisula L, Rysä J, Kärkkäinen O. Parental cigarette smoking before
457 and during pregnancy in a cohort of 21 472 pregnancies. *Basic Clin Pharmacol Toxicol*.
458 2024;134(4):543-555. doi:10.1111/bcpt.13987

459 18. Lehikoinen AI, Kärkkäinen OK, Lehtonen MAS, Auriola SOK, Hanhineva KJ, Heinonen ST.
460 Alcohol and substance use are associated with altered metabolome in the first
461 trimester serum samples of pregnant mothers. *Eur J Obstet Gynecol Reprod Biol*.
462 2018;223:79-84. doi:10.1016/j.ejogrb.2018.02.004

463 19. Klåvus A, Kokla M, Noerman S, et al. “notame”: Workflow for Non-Targeted LC-MS
464 Metabolic Profiling. *Metabolites*. 2020;10(4):135. doi:10.3390/metabo10040135

465 20. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for
466 chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards
467 Initiative (MSI). *Metabolomics Off J Metabolomic Soc*. 2007;3(3):211-221.
468 doi:10.1007/s11306-007-0082-2

469 21. Wishart DS, Guo A, Oler E, et al. HMDB 5.0: the Human Metabolome Database for 2022.
470 *Nucleic Acids Res*. 2022;50(D1):D622-D631. doi:10.1093/nar/gkab1062

471 22. Tappin DM, Ford RP, Schluter PJ. Smoking during pregnancy measured by population
472 cotinine testing. *N Z Med J*. 1997;110(1050):311-314.

23. Nenezic N, Kostic S, Strac DS, et al. Dehydroepiandrosterone (DHEA): Pharmacological Effects and Potential Therapeutic Application. *Mini Rev Med Chem*. 2023;23(8):941-952. doi:10.2174/1389557522666220919125817

24. Baron JA, Comi RJ, Cryns V, Brinck-Johnsen T, Mercer NG. The effect of cigarette smoking on adrenal cortical hormones. *J Pharmacol Exp Ther*. 1995;272(1):151-155.

25. Cora N, Ghandour J, Pollard CM, et al. Nicotine-induced adrenal beta-arrestin1 upregulation mediates tobacco-related hyperaldosteronism leading to cardiac dysfunction. *World J Cardiol*. 2020;12(5):192-202. doi:10.4330/wjc.v12.i5.192

26. Yan Y, Guo F, Liu K, Ding R, Wang Y. The effect of endocrine-disrupting chemicals on placental development. *Front Endocrinol*. 2023;14:1059854. doi:10.3389/fendo.2023.1059854

27. Kenny LC, SCOPE Consortium, Brown LW, Ortea P, Tuytten R, Kell DB. Relationship between the concentration of ergothioneine in plasma and the likelihood of developing pre-eclampsia. *Biosci Rep*. 2023;43(7):BSR20230160. doi:10.1042/BSR20230160

28. Smith E, Ottosson F, Hellstrand S, et al. Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease. *Heart Br Card Soc*. 2020;106(9):691-697. doi:10.1136/heartjnl-2019-315485

29. Hinds TD, Stec DE. Bilirubin, a Cardiometabolic Signaling Molecule. *Hypertens Dallas Tex 1979*. 2018;72(4):788-795. doi:10.1161/HYPERTENSIONAHA.118.11130

30. Kodal JB, Çolak Y, Kobylecki CJ, Vedel-Krogh S, Nordestgaard BG, Afzal S. Smoking Reduces Plasma Bilirubin: Observational and Genetic Analyses in the Copenhagen General Population Study. *Nicotine Tob Res Off J Soc Res Nicotine Tob*. 2020;22(1):104-110. doi:10.1093/ntr/nty188

31. Kim NH, Kim HC, Lee JY, Lee JM, Suh I. Active and Passive Smoking and Serum Total Bilirubin in a Rural Korean Population. *Nicotine Tob Res Off J Soc Res Nicotine Tob*. 2016;18(5):572-579. doi:10.1093/ntr/ntv251

32. Weaver L, Hamoud AR, Stec DE, Hinds TD. Biliverdin reductase and bilirubin in hepatic disease. *Am J Physiol Gastrointest Liver Physiol*. 2018;314(6):G668-G676. doi:10.1152/ajpgi.00026.2018

33. Koh M, Ahmad I, Ko Y, et al. A short ORF-encoded transcriptional regulator. *Proc Natl Acad Sci U S A*. 2021;118(4):e2021943118. doi:10.1073/pnas.2021943118

34. Hamaue N. [Pharmacological role of isatin, an endogenous MAO inhibitor]. *Yakugaku Zasshi*. 2000;120(4):352-362. doi:10.1248/yakushi1947.120.4_352

506 35. Buneeva OA, Kapitsa IG, Kazieva LS, Vavilov NE, Zgoda VG. Quantitative changes of
507 brain isatin-binding proteins of rats with the rotenone-induced experimental
508 parkinsonism. *Biomeditsinskaia Khimiia*. 2023;69(3):188-192.
509 doi:10.18097/PBMC20236903188

510 36. Bowker K, Lewis S, Coleman T, Cooper S. Changes in the rate of nicotine metabolism
511 across pregnancy: a longitudinal study. *Addict Abingdon Engl*. 2015;110(11):1827-1832.
512 doi:10.1111/add.13029

513 37. Qian J, Chen Q, Ward SM, Duan E, Zhang Y. Impacts of Caffeine during Pregnancy.
514 *Trends Endocrinol Metab TEM*. 2020;31(3):218-227. doi:10.1016/j.tem.2019.11.004

515 38. Yu T, Campbell SC, Stockmann C, et al. Pregnancy-induced changes in the
516 pharmacokinetics of caffeine and its metabolites. *J Clin Pharmacol*. 2016;56(5):590-596.
517 doi:10.1002/jcph.632

518 39. Hey E. Coffee and pregnancy. *BMJ*. 2007;334(7590):377.
519 doi:10.1136/bmj.39122.395058.80

520 40. Jin F, Qiao C. Association of maternal caffeine intake during pregnancy with low birth
521 weight, childhood overweight, and obesity: a meta-analysis of cohort studies. *Int J Obes*
522 *2005*. 2021;45(2):279-287. doi:10.1038/s41366-020-0617-4

523 41. Huffman SL, Harika RK, Eilander A, Osendarp SJM. Essential fats: how do they affect
524 growth and development of infants and young children in developing countries? A
525 literature review. *Matern Child Nutr*. 2011;7 Suppl 3(Suppl 3):44-65. doi:10.1111/j.1740-
526 8709.2011.00356.x

527 42. Jääskeläinen T, Kärkkäinen O, Jokkala J, et al. A non-targeted LC-MS metabolic profiling
528 of pregnancy: longitudinal evidence from healthy and pre-eclamptic pregnancies.
529 *Metabolomics Off J Metabolomic Soc*. 2021;17(2):20. doi:10.1007/s11306-020-01752-5

530 43. Kitchen S, Adcock DM, Dauer R, et al. International Council for Standardization in
531 Haematology (ICSH) recommendations for processing of blood samples for coagulation
532 testing. *Int J Lab Hematol*. 2021;43(6):1272-1283. doi:10.1111/ijlh.13702

533

534 Table 1: Background characteristics of the study women.

Maternal characteristics					
	Controls n=117		**Cases n=99**		**p value**
Maternal age (years, mean; ±SD)	28.4	±5.7	27.4	±5.7	0.192 [a]
Maternal height (cm, mean; ±SD)	163.9	±5.6	165.3	±5.5	0.077 [a]
Maternal weight, kg (pre-pregnancy) (mean; ±SD)	**64.2**	**±14.0**	**69.5**	**±13.8**	**0.006[a]**
Maternal BMI kg/m2 (mean; ±SD)	**23.8**	**±4.9**	**25.5**	**±5.1**	**0.020 [a]**
Parity (N, mean; SD)	**1.7**	**±2.2**	**1.2**	**±1.2**	**0.026 [a]**
Gravidity (N, mean; SD)	3.3	±2.8	3.1	±1.9	0.522 [a]
Duration of pregnancy at birth (days, mean; SD)	278	±11	277	±15	0.566 [a]
Hospital stay after birth, days (mean; SD)	3.3	±1.7	3.7	±2.7	0.152 [a]
In a relationship (n, %)	**108**	**92%**	**62**	**63%**	**<0.0001 [b]**
Cigarettes per day before pregnancy (mean; ±SD)	**0**	**±0**	**15.2**	**±6.3**	**<0.0001 [a]**
Cigarettes per day during pregnancy (mean; ±SD)	**0**	**±0**	**6.3**	**±4.0**	**<0.0001 [a]**
Smoking Index (mean; SD)	**0**	**±0**	**2.4**	**±0.9**	**<0.0001 [a]**
Characteristics of the newborns					
Female (n, %)	57	49%	43	43%	0.438[b]
Birth weight (g, mean ±SD)	**3552**	**±513**	**3397**	**±534**	**0.032**
Head circumference (cm, mean; ±SD)	**35.2**	**±1.4**	**34.7**	**±1.6**	**0.020[a]**
Placenta weight (grams, mean; ±SD)	618.6	±141.4	605.5	±135.0	0.489 [a]
APGAR scores 1 min (mean; ±SD)	8.8	±1.0	8.	±1.1	0.615 [a]

APGAR scores 5 min (mean; ±SD)	8.9	±1.3	9.0	±0.8	0.611[a]
Child's special care after birth (n, %)	**13**	**11%**	**21**	**21%**	**0.042 [b]**
Need for treatment in Neonatal Intensive Care Unit (n, %)	**10**	**8.5%**	**21**	**21%**	**0.008 [b]**
Ventilation assistance (n, %)	0	0%	1	1%	0.276[b]
Intubation (%)	0	0%	1	1%	0.276 [b]
Postnatal antibiotic treatment (n, %)	**4**	**3.4%**	**13**	**13.1%**	**0.008 [b]**
Phototherapy (%)	5	4.3%	5	5%	0.787 [b]
Malformations (%)	1%	0.9%	0	0%	0.357[b]

Legend: [a] Welch's t test; [b] Chi^2 test.

538 **Figure legends:**



539

540 **Figure 1:** Overview of metabolite profiling from the first trimester maternal plasma

541 samples. A total of 9600 molecular features were observed from the chosen samples. Panel

542 **A** shows the outcomes of the principal component analysis (PCA). A total of 184

543 components were needed to account for 95% of the variance in the data. PC1 (t1) explained

544 4.5 % of the variation in the data, and PC2 (t2) explained 4.3% of the data. Panel **B** shows

545 partial least squares discriminant analysis (PLS-DA) which illustrates the good separation

546 between the study groups (6 components, cum R2Y = 0.99, Q2 = 0.70). Panel **C** shows the p

547 values (Welch's t-test), Cohen's d effect sizes, and VIP values from the PLS-DA) of all of the
548 relevant molecular features. A total of 193 molecular features were significantly altered
549 between the smokers' and nonsmokers' samples (adjusted α level= 0.0003, Bonferroni's
550 correction).


Cotinine
<0.0001
Abundance
Control Cases
d = 3.00
VIP = 6.11
Nicotine
<0.0001
Abundance
Control Cases
d = 2.51
VIP = 5.63
3-Hydroxypyridine
<0.0001
Abundance
Control Cases
d = 1.25
VIP = 4.32
DHEA-S
<0.0001
Abundance
Control Cases
d = 0.68
VIP = 2.70
Trigonelline
<0.0001
Abundance
Control Cases
d = 0.91
VIP = 3.28
Citropten
<0.0001
Abundance
Control Cases
d = 1.25
VIP = 4.32
Paraxanthine
<0.0001
Abundance
Control Cases
d = 0.95
VIP = 3.45
Caffeine
<0.0001
Abundance
Control Cases
d = 0.66
VIP = 2.59
Theophylline
0.0001
Abundance
Control Cases
d = 0.56
VIP = 2.21
Aminophenol
<0.0001
Abundance
Control Cases
d = 0.66
VIP = 2.62
LysoPC 16:1/0:0
<0.0001
Abundance
Control Cases
d = 0.59
VIP = 2.35
LysoPC 0:0/16:1
0.0003
Abundance
Control Cases
d = 0.51
VIP = 2.07
Aniline
0.0002
Abundance
Control Cases
d = 0.53
VIP = 2.16
Isatin
<0.0001
Abundance
Control Cases
d = -0.86
VIP = 3.19
PC 38:6 (16:0_22:6)
<0.0001
Abundance
Control Cases
d = -0.55
VIP = 2.24
Ergothioneine
0.0002
Abundance
Control Cases
d = -0.54
VIP = 1.95
Bilirubin
0.0002
Abundance
Control Cases
d = -0.53
VIP = 2.01
Biliverdin
0.0004
Abundance
Control Cases
d = -0.43
VIP = 1.56

551

552 **Figure 2:** Smokers show altered metabolite profile in the first-trimester plasma samples
553 when compared to nonsmoking controls. Box plots with whiskers (min and max) are shown
554 with p-value from a Welch's t-test (multiple testing adjusted α level was 0.0003). Biliverdin
555 result should be considered a trend. Abbreviations: DHEA-S, dehydroepiandrosterone
556 sulfate; PC, phosphatidylcholine.



Figure 3: Association between the birth weight of the newborn and metabolite levels in the first trimester of pregnancy. Three metabolites were positively associated with birth weight and four were negatively associated with birth weight. Abbreviations: AC 14.1: tetradecenoylcarnitine; Asp_Phe: Aspartyl-phenylalanine; PC: phosphatidylcholine; p: p-value, r: Pearson correlation coefficient



Figure 4: Correlations between the head circumference of the newborn and first trimester levels of metabolites. Six metabolites were negatively associated with differences in the head circumference between the groups. Abbreviations: AC 06:0, Hexanoylcarnitine; LysoPC: lysophosphatidylcholine, p: p-value, r: Pearson correlation coefficient